v3.24.1.u1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Timing of Revenue Recognition
The following table illustrates the timing of the Company’s revenue recognition patterns:
Three Months Ended March 31,
20242023
Software products and services – point in time48.7 %30.8 %
Software products and services – over time42.6 19.0 
Drug Discovery – point in time— 41.9 
Drug Discovery – over time8.7 8.3 
Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue
The following table presents the revenue recognized from the sources of software products and services revenue:
Three Months Ended March 31,
20242023
On-premise software$17,619 $19,944 
Hosted software7,176 4,451 
Software maintenance5,895 5,750 
Professional services2,725 2,068 
Revenue from contracts with customers33,415 32,213 
Software contribution— — 
Total software revenue$33,415 $32,213 
Drug Discovery Revenue
The following table presents the revenue recognized from the sources of drug discovery revenue:
Three Months Ended March 31,
20242023
Drug discovery services revenue from contracts with customers$2,692 $31,803 
Drug discovery contribution491 766 
Total drug discovery revenue$3,183 $32,569 
Schedule of Contract Balances
Contract balances were as follows:
As of
March 31,
2024		As of
December 31,
2023
Contract assets$23,902 $21,107 
Deferred revenue, short-term:
Software products and services39,537 44,218 
Drug discovery9,960 12,013 
Deferred revenue, long-term:
Software products and services1,961 2,407 
Drug discovery6,055 6,636